Moderna (MRNA) Liabilities and Shareholders Equity (2017 - 2025)
Moderna (MRNA) has disclosed Liabilities and Shareholders Equity for 9 consecutive years, with $12.3 billion as the latest value for Q4 2025.
- Quarterly Liabilities and Shareholders Equity fell 12.76% to $12.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.2 billion through Dec 2025, down 21.12% year-over-year, with the annual reading at $12.3 billion for FY2025, 12.76% down from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $12.3 billion at Moderna, up from $12.1 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $27.6 billion in Q1 2022, with the low at $12.0 billion in Q2 2025.
- Average Liabilities and Shareholders Equity over 5 years is $18.8 billion, with a median of $17.6 billion recorded in 2023.
- The sharpest move saw Liabilities and Shareholders Equity surged 513.97% in 2021, then crashed 30.66% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $24.7 billion in 2021, then increased by 4.82% to $25.9 billion in 2022, then dropped by 28.74% to $18.4 billion in 2023, then decreased by 23.25% to $14.1 billion in 2024, then dropped by 12.76% to $12.3 billion in 2025.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $12.3 billion, $12.1 billion, and $12.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.